Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Net Income (Common)
Bioporto A/S
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Income (Common)
-kr61.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-15%
|
|
|
Genmab A/S
CSE:GMAB
|
Net Income (Common)
kr7.8B
|
CAGR 3-Years
38%
|
CAGR 5-Years
29%
|
CAGR 10-Years
39%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income (Common)
-kr1.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-32%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income (Common)
-€378.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-44%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income (Common)
kr1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Net Income (Common)
-kr87.2m
|
CAGR 3-Years
40%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Net Income (Common)?
Net Income (Common)
-61.3m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Net Income (Common) amounts to -61.3m DKK.
What is Bioporto A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-15%
Over the last year, the Net Income (Common) growth was 13%. The average annual Net Income (Common) growth rates for Bioporto A/S have been -4% over the past three years , and -15% over the past ten years .
You don't have any saved screeners yet